TIGIT and Miyoshi myopathy: In summary macrophages from BM of all 3 solid tumors and of the MM lesions were also found to express two target molecules of the TIGIT pathway more frequently in each tumor type than in NMC aspirates (BC: TIGIT, PVRL4; PC: TIGIT, PVRL4; NSCLC: CD112, CD155; MM: TIGIT, CD155).